viewKazia Therapeutics Ltd

Kazia Therapeutics awarded US FDA Orphan Drug Designation to paxalisib treatment for malignant glioma

This status for potential treatments for rare diseases provides a period of 7.5 years data exclusivity (for a paediatric disease), which allows developers to extend the effective life of a commercial product.

Kazia Therapeutics Ltd - Kazia Therapeutics secures FDA Orphan Drug Designation for its Paxalisib treatment for malignant glioma
Kazia previously received ODD for paxalisib in glioblastoma in February 2018

Kazia Therapeutics Ltd’s (ASX:KZA) (NASDAQ:KZIA) paxalisib treatment for malignant glioma has been granted Orphan Drug Designation (ODD) by the United States Food and Drug Administration (FDA).

The treatment includes Diffuse Intrinsic Pontine Glioma (DIPG), a rare and highly aggressive childhood brain cancer.

Kazia chief executive officer Dr James Garner said: “This award of ODD concludes a program of regulatory optimisation that Kazia has initiated for paxalisib over the past six months.

“As we orient paxalisib towards commercialisation, these special designations from FDA will allow us to move forward in the swiftest and most effective way possible.”

Shares have been more than 15% higher in early trade to A$1.13 and have risen from A$0.515 at the market close on August 4.

Orphan Drug Designation status

ODD is a special status accorded to drugs which are considered promising potential treatments for rare (orphan) diseases, generally defined as those which affect less than 200,000 cases per annum in the United States.

It can provide drug developers with up to seven years of Orphan Drug Exclusivity (ODE), extending the effective life of a commercial product.

ODD status also provides opportunities for orphan grant funding by the FDA, as well as protocol assistance, and financial benefits, such as a waiver of new drug application fees under the Prescription Drug User Fees Act (PDUFA fees), which are just under US$3 million in FY2020.

Rare paediatric disease designation

The receipt of ODD follows award of Rare Paediatric Disease Designation (RPDD) for DIPG on August 7, 2020.

Dr Garner said: “Taken together, RPDD and ODD provide a powerful suite of incentives, opportunities and protections for the development of paxalisib in DIPG.

“We look forward to seeing initial data from the ongoing phase I study in DIPG at St Jude Children’s Research Hospital during the second half of calendar 2020.

“In parallel, we are working closely with collaborators, advisors, and researchers to determine the best path forward for paxalisib in this devastating disease.”

Summary of Paxalisib regulatory status to date. 

Next steps

Kazia expects to present further data from its ongoing phase II study of paxalisib in glioblastoma at the Society for Neuro-Oncology (SNO) Annual Meeting in November 2020.

Precise timing remains uncertain due to pandemic-related disruption in conference schedules, but the company expects to provide an update to investors at the earliest opportunity.

Paxalisib has been selected to join the international GBM AGILE pivotal study in glioblastoma, and recruitment is expected to begin in the second half of 2020.

Quick facts: Kazia Therapeutics Ltd

Price: 1.32 AUD

Market: ASX
Market Cap: $166.54 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...


Kintara Therapeutics and Kazia Therapeutics begin trial to treat deadly...

Kintara Therapeutics Inc (NASDAQ:KTRA) CEO Saiid Zarrabian tells Proactive that its drug VAL-083 has been activated for an adaptive platform recurrent glioblastoma (GBM) trial. Zarrabian says Kintara, along with Kazia Therapeutics Limited (ASX:KZA) (NASDAQ:KZIA) and its drug paxalisib, will...

on 01/06/2021

3 min read